Wonbiogen Q1 Revenue 9.28B Won, Operating Profit 2.12B Won, Share Buyback and Dividend Declared

Consolidated revenue 9.28B won, up 12.4% YoY; operating profit 2.12B won with 22.8% margin
Net profit attributable to parent 1.67B won, up 34.7% YoY
Acquired 217,073 treasury shares (approx. 1.53B won) during the quarter, ending with 217,073 shares
Cash dividend approved at 8th AGM, unpaid dividend of 0.99B won recognized
Litigation risk: 1 lawsuit as defendant (20B won claim), provisional attachment on buildings (49B won)
Debt ratio improved to 18.3% from 31.6% at year-end 2025
R&D expenses increased to 0.21B won (separate), new product development ongoing